Physician profile
Gregory D Smith
NPI 1659375269
$1,876.46
in general payments reported to CMS, 2019-2025
35 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $12.87 · 2021: $251 · 2022: $225 · 2023: $143 · 2024: $191 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $255.36 | 2021-2025 | Sublocade |
| Astellas Pharma US INC | $224.10 | 2019 | |
| Abbvie INC. | $189.12 | 2021-2025 | Mavyret, Vraylar |
| Gilead Sciences, INC. | $176.14 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $119.70 | 2025 | Voquezna |
| Novo Nordisk INC | $101.13 | 2019 | |
| Glaxosmithkline, LLC. | $86.59 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $81.04 | 2022-2025 | Rexulti |
| Medtronic, INC. | $65.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.69 | 2019 | |
| Uswm, LLC | $38.75 | 2022-2024 | Lucemyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.08 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.99 | 2019 | |
| Alkermes, INC. | $32.20 | 2019-2025 | Lybalvi |
| Abiomed | $30.78 | 2024 | Impella |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $29.28 | 2024-2025 | Azstarys |
| Pear Therapeutics (US), INC. | $27.22 | 2022 | |
| Amgen INC. | $24.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.29 | 2019 | |
| Axsome Therapeutics, INC. | $19.84 | 2025 | Auvelity |
| Tris Pharma INC | $19.84 | 2024 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2023 | Quviviq |
| Amarin Pharma, INC. | $16.32 | 2019 | |
| Braeburn INC. | $14.43 | 2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $14.06 | 2019 | |
| Pfizer INC. | $13.15 | 2019 | |
| Dentsply Sirona INC | $12.87 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.70 | 2019 | |
| Allergan, INC. | $12.43 | 2019 | |
| Merck Sharp & Dohme LLC | $11.88 | 2019 | |
| Medtronic USA, INC. | $11.70 | 2019 | |
| Genentech USA, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.